Cargando…

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer

A leading theory for ovarian carcinogenesis proposes that inflammation associated with incessant ovulation is a driver of oncogenesis. Consistent with this theory, nonsteroidal anti-inflammatory drugs (NSAIDs) exert promising chemopreventive activity for ovarian cancer. Unfortunately, toxicity is as...

Descripción completa

Detalles Bibliográficos
Autores principales: Borneman, Rebecca M., Gavin, Elaine, Musiyenko, Alla, Richter, Wito, Lee, Kevin J., Crossman, David K., Andrews, Joel F., Wilhite, Annelise M., McClellan, Steven, Aragon, Ileana, Ward, Antonio B., Chen, Xi, Keeton, Adam B., Berry, Kristy, Piazza, Gary A., Scalici, Jennifer M., da Silva, Luciana Madeira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632086/
https://www.ncbi.nlm.nih.gov/pubmed/36324187
http://dx.doi.org/10.1186/s13048-022-01050-9
_version_ 1784823955587072000
author Borneman, Rebecca M.
Gavin, Elaine
Musiyenko, Alla
Richter, Wito
Lee, Kevin J.
Crossman, David K.
Andrews, Joel F.
Wilhite, Annelise M.
McClellan, Steven
Aragon, Ileana
Ward, Antonio B.
Chen, Xi
Keeton, Adam B.
Berry, Kristy
Piazza, Gary A.
Scalici, Jennifer M.
da Silva, Luciana Madeira
author_facet Borneman, Rebecca M.
Gavin, Elaine
Musiyenko, Alla
Richter, Wito
Lee, Kevin J.
Crossman, David K.
Andrews, Joel F.
Wilhite, Annelise M.
McClellan, Steven
Aragon, Ileana
Ward, Antonio B.
Chen, Xi
Keeton, Adam B.
Berry, Kristy
Piazza, Gary A.
Scalici, Jennifer M.
da Silva, Luciana Madeira
author_sort Borneman, Rebecca M.
collection PubMed
description A leading theory for ovarian carcinogenesis proposes that inflammation associated with incessant ovulation is a driver of oncogenesis. Consistent with this theory, nonsteroidal anti-inflammatory drugs (NSAIDs) exert promising chemopreventive activity for ovarian cancer. Unfortunately, toxicity is associated with long-term use of NSAIDs due to their cyclooxygenase (COX) inhibitory activity. Previous studies suggest the antineoplastic activity of NSAIDs is COX independent, and rather may be exerted through phosphodiesterase (PDE) inhibition. PDEs represent a unique chemopreventive target for ovarian cancer given that ovulation is regulated by cyclic nucleotide signaling. Here we evaluate PDE10A as a novel therapeutic target for ovarian cancer. Analysis of The Cancer Genome Atlas (TCGA) ovarian tumors revealed PDE10A overexpression was associated with significantly worse overall survival for patients. PDE10A expression also positively correlated with the upregulation of oncogenic and inflammatory signaling pathways. Using small molecule inhibitors, Pf-2545920 and a novel NSAID-derived PDE10A inhibitor, MCI-030, we show that PDE10A inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis. We demonstrate these pro-apoptotic properties occur through PKA and PKG signaling by using specific inhibitors to block their activity. PDE10A genetic knockout in ovarian cancer cells through CRISP/Cas9 editing lead to decreased cell proliferation, colony formation, migration and invasion, and in vivo tumor growth. We also demonstrate that PDE10A inhibition leads to decreased Wnt-induced β-catenin nuclear translocation, as well as decreased EGF-mediated activation of RAS/MAPK and AKT pathways in ovarian cancer cells. These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-022-01050-9.
format Online
Article
Text
id pubmed-9632086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96320862022-11-04 Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer Borneman, Rebecca M. Gavin, Elaine Musiyenko, Alla Richter, Wito Lee, Kevin J. Crossman, David K. Andrews, Joel F. Wilhite, Annelise M. McClellan, Steven Aragon, Ileana Ward, Antonio B. Chen, Xi Keeton, Adam B. Berry, Kristy Piazza, Gary A. Scalici, Jennifer M. da Silva, Luciana Madeira J Ovarian Res Research A leading theory for ovarian carcinogenesis proposes that inflammation associated with incessant ovulation is a driver of oncogenesis. Consistent with this theory, nonsteroidal anti-inflammatory drugs (NSAIDs) exert promising chemopreventive activity for ovarian cancer. Unfortunately, toxicity is associated with long-term use of NSAIDs due to their cyclooxygenase (COX) inhibitory activity. Previous studies suggest the antineoplastic activity of NSAIDs is COX independent, and rather may be exerted through phosphodiesterase (PDE) inhibition. PDEs represent a unique chemopreventive target for ovarian cancer given that ovulation is regulated by cyclic nucleotide signaling. Here we evaluate PDE10A as a novel therapeutic target for ovarian cancer. Analysis of The Cancer Genome Atlas (TCGA) ovarian tumors revealed PDE10A overexpression was associated with significantly worse overall survival for patients. PDE10A expression also positively correlated with the upregulation of oncogenic and inflammatory signaling pathways. Using small molecule inhibitors, Pf-2545920 and a novel NSAID-derived PDE10A inhibitor, MCI-030, we show that PDE10A inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis. We demonstrate these pro-apoptotic properties occur through PKA and PKG signaling by using specific inhibitors to block their activity. PDE10A genetic knockout in ovarian cancer cells through CRISP/Cas9 editing lead to decreased cell proliferation, colony formation, migration and invasion, and in vivo tumor growth. We also demonstrate that PDE10A inhibition leads to decreased Wnt-induced β-catenin nuclear translocation, as well as decreased EGF-mediated activation of RAS/MAPK and AKT pathways in ovarian cancer cells. These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-022-01050-9. BioMed Central 2022-11-02 /pmc/articles/PMC9632086/ /pubmed/36324187 http://dx.doi.org/10.1186/s13048-022-01050-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Borneman, Rebecca M.
Gavin, Elaine
Musiyenko, Alla
Richter, Wito
Lee, Kevin J.
Crossman, David K.
Andrews, Joel F.
Wilhite, Annelise M.
McClellan, Steven
Aragon, Ileana
Ward, Antonio B.
Chen, Xi
Keeton, Adam B.
Berry, Kristy
Piazza, Gary A.
Scalici, Jennifer M.
da Silva, Luciana Madeira
Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
title Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
title_full Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
title_fullStr Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
title_full_unstemmed Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
title_short Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
title_sort phosphodiesterase 10a (pde10a) as a novel target to suppress β-catenin and ras signaling in epithelial ovarian cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632086/
https://www.ncbi.nlm.nih.gov/pubmed/36324187
http://dx.doi.org/10.1186/s13048-022-01050-9
work_keys_str_mv AT bornemanrebeccam phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT gavinelaine phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT musiyenkoalla phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT richterwito phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT leekevinj phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT crossmandavidk phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT andrewsjoelf phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT wilhiteannelisem phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT mcclellansteven phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT aragonileana phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT wardantoniob phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT chenxi phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT keetonadamb phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT berrykristy phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT piazzagarya phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT scalicijenniferm phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer
AT dasilvalucianamadeira phosphodiesterase10apde10aasanoveltargettosuppressbcateninandrassignalinginepithelialovariancancer